Advanced Malignancy Clinical Trial
Outcomes after in-hospital cardiopulmonary resuscitation (CPR) are very poor, particularly in patients with oxygen dependent chronic obstructive pulmonary disease (COPD) or metastatic cancer. Recent work found that in-hospital CPR is being performed more often before death with unchanging survival and that fewer CPR survivors are being discharged home, thus suggesting that CPR is increasingly performed without benefit and that the burden of this ineffective treatment is increasing. Unlike other medical procedures, CPR has become the default provided to all patients even those with tremendously poor outcomes. It is time to change the paradigm of CPR. Through comparing an innovative "informed assent" approach toward in-hospital CPR (informing patients that their underlying chronic illness makes outcomes of CPR so poor that CPR is not performed while allowing them to disagree) versus usual care in a group of chronically ill patients with reduced life expectancy, the investigators aspire to demonstrate that CPR delivery can be reduced. And in addition that DNR status increases, while preserving patient quality of life and decreasing the burden of this ineffective treatment to both patients and families. If effective, this informed assent intervention has the potential to revolutionize how the investigators discuss CPR with the investigators chronically ill patients.
n/a
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00978926 -
A Study of the Pharmacodynamic Effects of Anti-Vascular Endothelial Growth Factor Therapy in Patients With Advanced Malignancies
|
N/A | |
| Completed |
NCT01444404 -
A Study of AMG 820 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00428545 -
Bevacizumab and Bortezomib in Patients With Advanced Malignancy
|
Phase 1 | |
| Completed |
NCT02743637 -
A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors
|
Phase 1 | |
| Completed |
NCT01253707 -
A Study of AMG 337 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01723020 -
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT00813384 -
A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00974896 -
QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT02110355 -
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
|
Phase 1 | |
| Completed |
NCT02978482 -
A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT00858377 -
A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT04216082 -
A Study of Anlotinib in Subjects With Advanced Malignancy
|
Phase 2 | |
| Terminated |
NCT02437916 -
Safety Study of AMG 228 to Treat Solid Tumors
|
Phase 1 | |
| Terminated |
NCT01231347 -
QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas
|
Phase 3 | |
| No longer available |
NCT01945164 -
XL999 Administered Intravenously to a Subject With Advanced Malignancies
|
N/A | |
| Completed |
NCT03875157 -
Study of IBI318 in Participants With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT02016729 -
A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia
|
Phase 1 |